Teva Pharmaceutical $TEVAIt couldn't' break first fibonacci level and rsi 50. It is going down for double bottom?
TEVA trade ideas
TEVA Pharmaceuticals Potentially forming a Falling Wedge BottomIn my experience trendly / volatile stocks have a tendency to have significant long term reversals from wedges and general downtrendline breaks. Extremely interested to see where this goes, if it does end up breaking out bullishly. Company could begin a new bull run, or simply reach target and mean revert.
Juicy After Hours MoveI've been thinking the bottom was near considering Teva is a pharmaceutical company. With the news of Israel shutting down (with exception of grocery/pharmacy) due to the Corona Virus, we may have the catalyst we needed for a reversal. Business will not be effected and opiate settlement will be hard to continue to fight with governments needing all pharma on deck. BUY BUY BUY.
Teva Pharmaceutical Industries Ltd covic-19 Teva will donate 6 Million tablets through wholesalers to hospitals by March 31, and more than 10 Million within a month
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the immediate donation of more than 6 million doses of hydroxychloroquine sulfate tablets through wholesalers to hospitals across the U.S. to meet the urgent demand for the medicine as an investigational target to treat COVID-19. The company is also looking at additional ways to address the global need.
"We are committed to helping to supply as many tablets as possible as demand for this treatment accelerates at no cost," said Brendan O’Grady, Teva Executive Vice President, North America Commercial. "Immediately upon learning of the potential benefit of hyroxychloroquine, Teva began to assess supply and to urgently acquire additional ingredients to make more product while arranging for all of what we had to be distributed immediately."
Additional production of hydroxychloroquine sulfate tablets is also being assessed and subsequently ramped up with materials that are being sent to Teva from our ingredient supplier. Teva will ship 6 Million tablets through wholesalers to hospitals by March 31, and more than 10 Million within a month.
Hydroxychloroquine sulfate tablets manufactured by Teva are approved by U.S. Food and Drug Administration (FDA) for the treatment of malaria, lupus erythematosus and rheumatoid arthritis. Although the product is not currently approved for use in the treatment of COVID-19, it is currently under investigation for efficacy against the coronavirus and has been requested by US government officials to be made available for use immediately. The Company is also reviewing supply of both hydroxychloroquine and chloroquine globally to determine whether there are additional supply and access opportunities for patients.
Teva is also actively looking across its expansive range of products to determine if the company can help to provide any other products that may be relevant in addressing acute and substantial need during the COVID-19 crisis.
Speculative High-Return Idea - LONG "TEVA"I'm not gonna explain the fundamental data of the company for a long time, but I will say briefly that if you look at the dynamics of changes in the company's data, you can see a stable growth of the EPS indicators and a gradual moving towards a positive P&L. It is also indicative that with the huge fall of markets last week, the company did not “fly down” after the market. In the pharmaceutical sector, which itself is risky for investors, TEVA in recent months has shown good growth and the POTENTIAL for the long-term trend to transition from falling to rising. It has already broken up the resistance line lasting from the highest 2015 year point.
However, the idea of this post is no longer in long-term investment in this asset, but in speculative buying. The graph clearly shows the divergence of the asset price lows and its RSI and MACD indicators. According to Fibonacci, the stock adjusted to the desired level. Perhaps the fall to the level of 3703 Israeli Shekels and a rebound, or a rebound will be tomorrow. In any case, it is recommended to wait until the RSI fixes above 30 on the 1-hour chart, and then go into the idea. The way out of the idea is at least 4100 Shekels. Stop loss at your discretion, but 3650 is recommended.
If you do not have access to the Israeli market, then do not be discouraged, paper is also listed in America under the same name TEVA
P.S. It’s up to you to enter long-term or speculate, I recommend speculating only because I myself am a short-term speculator.
Cup and HandleThe chart depicts a classic cup and handle formation. Place a stop buy order slightly above the upper trend line of the handle. There is a risk of missing the trade if the price continues to advance and does not pull back.
TEVA is still undervalued compared to fair value - they reported positive drug trial data in Japan, and had a nice breakout this week.
gl!
TEVA Pharma breakout Teva Pharmaceutical Industries (NYSE:TEVA) Q4 results:
Revenues:$4,468M (+1%); North America: $2,373M (+6%); Generics: $2,497M (+2%), Copaxone: $387M (-22%).
Net income: $110M (+104%); non-GAAP net income: $683M (+26%); EPS: ($0.91); non-GAAP EPS: $0.10 (+104%).
Consensus was non-GAAP EPS of $0.61 on revenues of $4.35B.
Cash flow ops (full year): $748M (-69%). Decrease mainly due to the working capital adjustment with Allergan and the Rimsa settlement in 2018 and lower profits in North America in 2019.
Cash flow ops in Q4: $538M (+47%).
All components of 2019 outlook met, including spend base reduction target of $3B.
2020 guidance: Revenues: $16.6B - 17.0B; Copaxone sales: ~$1.2B; Austedo sales: ~$650M; AJOVY sales: ~$250M; non-GAAP EPS: $2.30 - 2.55; free cash flow: $1.8B - 2.2B.
Source Seeking ALPHA
TEVA Accumulation Stronger than SPX NYSE:TEVA AMEX:SPY
Teva - looks like Accumulation and starting to rise before Earnings next week
Teva have Good Sentiment after new product that gave company reason to be optimistic
small Entry and Adding last week
Target with P&F looks for 17.5 - 18 for now
will follow
Have A great Week
TevaTeva Pharmaceuticals releases earnings in 6 days on February 11 2020.
Potential Price Support-restance levels. The green box is the current difference maker for the upside, in which they it could aim to create a a 9 week: 13:10 and/or 10-week high 10:81 8 month high:15:44
:12 month: 15:91
The red line is the is still the long term support/resistance. 9.88
TEVA - Break-Out of Cup and Handle formationTEVA Breaking out with heavy volume of a cup and handle formation. Target to fill gap of $14-$15.
$TEVA long to $12, possible $15-$20Long $TEVA to at least $12 this week on technical basis alone. Could go for $15-$20 into March depending on earnings report on 2/12. DYOD - do your own due-diligence.
Love this stock 13PT +Even in a down market this one holds and waits to jump up. See chart. Easy 13 in a month or 2.
Long Idea Weekly15/Jan/2020 06:38 PM AUTHOR: Brandon Gum
--
Not sure on the target leading to the low RR.
New RSI confirms the move.
======================
Teva Pharma Bullish Golden CrossBeautiful recovery from the lows.
Volume is increasing.
Moving averages in Bullish formation.
MACd and Histogram, Bullish.
TEVA BULLISH FLAGBuyer s have broken upper trend line on a Bullish flag pattern confirmed the entry which was backed by huge volume, Of we go
Great opportunity coming up Teva is going to hit a major resistance line causing a bounce back making two very high-profit scenarios that can be taken advantage of. I would recommend a entry of $8.50 or higher and an exit with your own judgment and stop losses.
Daily inverted hammer bullish PT 13.5Love this stock for upside play, last daily candle formed a inverted hammer (Bullish) Great long term play
